Recent News & Research

*September 2025* The ACROSS 2 trial comparing aumolertinib, a third-generation EGFR-TKI, with and without platinum-based chemotherapy, found that combination therapy improved progression-free survival (PFS) for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who also had co-mutated tumor suppressor genes (TSGs). The PFS benefit was modest, 19.8 months for combination…

*September 2025* This is the slide deck from AstraZeneca's Global Lung Cancer Advocacy Exchange at the 2025 WCLC in Barcelona. You can access the slides here.

*August 2025* In this episode of the Oncology Brothers podcast, we had the pleasure of discussing the recent FDA approval of datopotamab deruxtecan (Dato-DXd) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). We were joined by Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, who…

*October 2025* Highlights Clinical Impact of Histological Transformation NSCLC-to-SCLC transformation drives resistance to targeted and immune therapies in EGFR-mutant cases, leading to aggressive disease with poor outcomes that demands new management approaches.  Mechanisms Driving Transformation RB1/TP53 loss enables transformation through lineage plasticity, supported by APOBEC hypermutation and dysregulation of MYC, NOTCH and…

*June 2025* Key Takeaways In recent research, a range of therapies showed favorable efficacy and safety results in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs) and/or chemotherapy. Among patients with EGFR-mutant and mesenchymal epithelial transition factor (MET)-amplification advanced…

*August 2025* Key Takeaways Zongertinib received FDA accelerated approval for HER2-mutant unresectable or metastatic nonsquamous NSCLC after prior systemic therapy. The phase 1 Beamion LUNG-1 trial showed a 71% objective response rate and favorable safety profile for zongertinib. Most treatment-related adverse effects were mild, with diarrhea and rash being the…

*January 2026* Abstract Purpose The role of local cranial radiation (LCR) combined with third-generation tyrosine kinase inhibitors (TKIs) in the following the progression to leptomeningeal metastasis (LM) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with brain metastasis (BM) remains unclear. This study investigates whether LCR combined…

*August 2025* Abstract Despite the efficacy of osimertinib in the first-line treatment of advanced EGFR-mutated NSCLC, the development of resistance is nearly inevitable. BRAF mutations and fusions are reported in 1% to 3% of patients with EGFR-mutated NSCLC receiving osimertinib and represent potential targetable alterations. In this case report, we discuss the rationale for…